Author:
Broderick William,Stiff Patrick
Reference43 articles.
1. Freedman AS, Nadler LM (1998) Malignancies of lymphoid cells. In: Fauci AS (ed) Harrison’s principles of internal medicine, 14th edn. McGraw-Hill, New York, p 708
2. Densmore JJ, Williams ME (2006) Lymphoproliferative diseases. In: Williams ME, Kahn MJ (eds) American society of hematology self-assessment program. Blackwell Publishing, Washington, DC, pp 260-264
3. Straus D, Portlock C, Qin J, Myers J (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, Vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) varsus ABVD alone for stages I, II, and IIIA non-bulky Hodgkin Disease. Blood 104:3483-3489
4. leMaignan C, Desablens B, Delwail V, Dib M, Berthou C (2004) Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103:58-66
5. Engert A, Franklin J, Eich H, Brillant C, Sehlen S, Cartoni C (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: Final results of the GHSG HD7 trial. J Clin Oncol 25:3495-3502